Incyte Corp. said it filed for marketing approval of its lead drug candidate ruxolitinib, and has asked regulators to make a decision on the cancer treatment by early December. The company said Monday that it asked the Food and Drug Administration to approve ruxolitinib as a treatment for myelofibrosis, a cancer of the blood.
